Filament is one of a small number of Canadian companies to have Good Manufacturing Practices-compliant psilocybin drug candidates entering Health Canada-approved clinical trials VANCOUVER, BC, Jan. 26, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that its wholly…


Previous articleMINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022
Next articlePsychedelic Perceptions in 2021: Popular Culture & Controversy